stars 1 stars 2 stars 3

iNANOD AS, an ambitious micro-pharma company revolutionising cancer treatment through targeted and faster drug delivery to solid malignant tumours. iNANOD utilizes nanotechnology to improve drug delivery within cancer chemotherapy, allowing for the targeted and accelerated delivery of active pharmaceutical ingredients. iNANOD founders envisioned a future where nanotechnology, in combination with biotechnology, could transform cancer treatment. iNANOD AS operates on a lean model, strongly supported by a group of experienced advisors, and is dedicated to improving the precision and efficiency of drug delivery to solid tumours. By leveraging market-pull mechanisms of innovation, the company aims to address one of the most pressing challenges in oncology: ensuring that a higher percentage of injected doses reach tumour sites, thereby enhancing treatment efficacy while minimising side effects.

iNANOD AS Questions

The iNANOD AS annual revenue was $2 million in 2026.

Nalinava Gupta is the Co-founder, CEO of iNANOD AS.

1 people are employed at iNANOD AS.

The NAICS codes for iNANOD AS are [32, 325].

The SIC codes for iNANOD AS are [283, 28].

Top iNANOD AS Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users